دورية أكاديمية
Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine.
| العنوان: | Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine. |
|---|---|
| المؤلفون: | Hermel DJ; Division of Hematology and Oncology, Scripps Clinic and Scripps MD Anderson, 10666 N. Torrey Pines Ave, La Jolla, CA, 92037, USA. hermel.david@scrippshealth.org., Cheng B; Division of Hematology and Oncology, Scripps Clinic and Scripps MD Anderson, 10666 N. Torrey Pines Ave, La Jolla, CA, 92037, USA., Bhangoo MS; Division of Hematology and Oncology, Scripps Clinic and Scripps MD Anderson, 10666 N. Torrey Pines Ave, La Jolla, CA, 92037, USA., Burian C; Division of Hematology and Oncology, Scripps Clinic and Scripps MD Anderson, 10666 N. Torrey Pines Ave, La Jolla, CA, 92037, USA., Waalen J; Scripps Research Translational Institute, La Jolla, CA, USA., Saven A; Division of Hematology and Oncology, Scripps Clinic and Scripps MD Anderson, 10666 N. Torrey Pines Ave, La Jolla, CA, 92037, USA. |
| المصدر: | Annals of hematology [Ann Hematol] 2022 May; Vol. 101 (5), pp. 1089-1096. Date of Electronic Publication: 2022 Feb 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Berlin : Springer Verlag Original Publication: Berlin ; New York : Springer International, c1991- |
| مواضيع طبية MeSH: | Antineoplastic Agents*/therapeutic use , Leukemia, Hairy Cell*/pathology, Aged ; Cladribine/therapeutic use ; Humans ; Remission Induction ; Retrospective Studies |
| مستخلص: | Hairy cell leukemia (HCL) is a rare hematologic disorder characterized by pancytopenia and splenomegaly for which a single course of cladribine is highly effective in inducing complete remissions. However, there is limited real-world data on outcomes and complications among geriatric patients with HCL treated with cladribine. We conducted a retrospective review of all patients 70 years or older within the Scripps Clinic HCL Database at the time of first treatment with cladribine. Of the 45 patients meeting inclusion criteria, 32 (71%) achieved CR and 4 (9%) achieved PR. Of the 9 remaining patients, 7 achieved normalization of peripheral blood counts after a single course of cladribine (complete hematologic response, CHR) and 2 had no response. The median duration of response for all responders was 119 months. Nine (20%) patients relapsed with a median time to first relapse of 28 months. Ten patients subsequently developed 12 primary malignancies with an excess frequency (observed-to-expected ratio) of 0.85 (95% confidence interval, 0.48-1.49). Median overall survival for the entire cohort was 166 months from time of HCL diagnosis and 119 months from time of first cladribine administration. Forty patient deaths were observed; the standardized mortality ratio (observed-to-expected ratio) was 1.42 (95% confidence interval, 1.03-1.96), representing a statistically significant increase in the risk of death (P = .03). This study supports the high rate of complete and durable responses following a single course of cladribine in geriatric patients. (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Robbins BA, Ellison DJ, Spinosa JC et al (1993) Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82(4):1277–1287. (PMID: 10.1182/blood.V82.4.1277.1277) Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305–2315. (PMID: 10.1056/NEJMoa1014209) Goodman GR, Burian C, Koziol JA, Saven A (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21(5):891–896. (PMID: 10.1200/JCO.2003.05.093) Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92(6):1918–1926. (PMID: 10.1182/blood.V92.6.1918) Spiers AS, Moore D, Cassileth PA et al (1987) Remissions in hairy-cell leukemia with pentostatin (2’-deoxycoformycin). N Engl J Med 316(14):825–830. (PMID: 10.1056/NEJM198704023161401) Grever MR, Abdel-Wahab O, Andritsos LA et al (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129(5):553–560. (PMID: 10.1182/blood-2016-01-689422) Tiacci E, Park JH, De Carolis L et al (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373(18):1733–1747. (PMID: 10.1056/NEJMoa1506583) Kreitman RJ, Tallman MS, Robak T et al (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30(15):1822–1828. (PMID: 10.1200/JCO.2011.38.1756) Kreitman RJ, Tallman MS, Robak T et al (2018) Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood 131(21):2331–2334. (PMID: 10.1182/blood-2017-09-803072) Chandran R, Gardiner SK, Smith SD, Spurgeon SE (2013) Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol 163(3):407–409. (PMID: 10.1111/bjh.12490) Else M, Dearden CE, Matutes E et al (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145(6):733–740. (PMID: 10.1111/j.1365-2141.2009.07668.x) Tallman MS, Hakimian D, Rademaker AW et al (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 88(6):1954–1959. (PMID: 10.1182/blood.V88.6.1954.bloodjournal8861954) Rosenberg JD, Burian C, Waalen J, Saven A (2014) Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 123(2):177–183. (PMID: 10.1182/blood-2013-06-508754) Paltiel O, Adler B, Barchana M, Dann EJ (2006) A population-based study of hairy cell leukemia in Israel. Eur J Haematol 77(5):372–377. (PMID: 10.1111/j.1600-0609.2006.00732.x) Sawhney R, Sehl M, Naeim A (2005) Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 11(6):449–460. (PMID: 10.1097/00130404-200511000-00004) Gomez H, Mas L, Casanova L et al (1998) Elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16(7):2352–2358. (PMID: 10.1200/JCO.1998.16.7.2352) Baraldi-Junkins CA, Beck AC, Rothstein G (2000) Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 14(1):45–61, viii. Yellen SB, Cella DF, Leslie WT (1994) Age and clinical decision making in oncology patients. J Natl Cancer Inst 86(23):1766–1770. (PMID: 10.1093/jnci/86.23.1766) Buske C, Hutchings M, Ladetto M, et al (2018) ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol. 29(3):544–562. Wildiers H, Heeren P, Puts M et al (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595–2603. (PMID: 10.1200/JCO.2013.54.8347) |
| فهرسة مساهمة: | Keywords: Cladribine; Durable responses; Geriatric; Hairy cell leukemia |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 47M74X9YT5 (Cladribine) |
| تواريخ الأحداث: | Date Created: 20220226 Date Completed: 20220412 Latest Revision: 20220412 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1007/s00277-022-04800-3 |
| PMID: | 35218397 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!